手術のための FVIII 治療が必要な血友病の女性/少女の管理における Nuwiq の投与量と結果
手術のために第 VIII 因子治療が必要な血友病の女性/少女の管理における Nuwiq の投与量と結果 - 国際非盲検非対照研究 (NuDIMENSION)
Recombinant factor VIII for the prevention of bleeding in women/girls with haemophilia A undergoing major surgery
調査の概要
詳細な説明
Female patients with mild to moderate haemophilia A will often need FVIII concentrates to provide haemostatic cover during major surgery. This prospective, open-label, non-controlled, single-arm, multinational, multicentre study aims to evaluate the overall perioperative haemostatic efficacy of Nuwiq in women/girls over 12 with haemophilia A undergoing major surgery requiring FVIII treatment
研究の種類
入学 (推定)
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前:Cristina Solomon
- 電話番号:+41795859042
- メール:cristina.solomon@octapharma.com
研究場所
-
-
Texas
-
San Antonio、Texas、アメリカ、78229
- 募集
- UT Health San Antonio
-
-
-
-
-
Leeds、イギリス
- 募集
- St. James's University Hospital
-
-
-
-
-
Catanzaro、イタリア
- 募集
- Aziendo Ospedaliera "Puglieze Ciaccio"
-
Palermo、イタリア
- 募集
- Policlinico "P. Giaconne"
-
-
Trentino-Alto Adige
-
Trento、Trentino-Alto Adige、イタリア
- 募集
- Santa Chiara Hospital - APSS
-
-
-
-
-
Montevideo、ウルグアイ
- まだ募集していません
- Centro Hospitalario Pereira Rossell
-
-
-
-
-
Bern、スイス
- 募集
- Insel Spital Bern
-
-
-
-
-
Madrid、スペイン
- 募集
- Hospital Universitario la Paz
-
Seville、スペイン
- 募集
- Hospital Universitario Virgen del Rocio
-
-
-
-
-
Belgrade、セルビア
- 募集
- Clinical Center for Serbia
-
-
-
-
-
Bonn、ドイツ
- 募集
- Universitätsklinikum Bonn,Institut für Experimentelle Haematologie und Transfusionsmedizin
-
Duisburg、ドイツ
- 募集
- Gerinnungszentrum Rhein-Ruhr
-
Hamburg、ドイツ
- 募集
- Universitätsklinikum Hamburg Eppendorf,II. Medizinische Klinik und Poliklinik
-
-
-
-
-
Helsinki、フィンランド
- 募集
- Helsinki University Hospital,Coagulation Disorder Unit
-
-
-
-
-
Chambray-lès-Tours、フランス
- 募集
- Avenue de la République
-
Nantes、フランス
- 募集
- CHU de Nantes Hôtel-Dieu
-
Strasbourg、フランス
- 募集
- Chu de Strasbourg
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Women/girls with haemophilia A (FVIII:C ≥1-<40%) according to medical history. Additionally, women/girls with documented FVIII activity levels between ≥ 40% and 50% may be included if there is a documented history of clinically significant bleeding episodes consistent with haemophilia A; and/or either documented prior treatment with FVIII concentrates or a clinical indication that FVIII treatment would have been appropriate (e.g., use of FVIII from a family member, or treatment with alternative haemostatic agents due to access limitations)
- At least 12 years of age
- Scheduled to undergo major surgery* requiring FVIII treatment, including elective and emergency procedures and caesarean section in pregnant women with haemophilia A
- Freely given written informed consent of the patient, or parent/legal representative where applicable, obtained in accordance with local regulations
Exclusion Criteria:
- Coagulation disorder other than haemophilia A
- Present or past FVIII inhibitor (≥0.6 Bethesda units [BU]/mL)
- Severe liver or kidney disease (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] levels >5 times the upper limit of normal; or creatinine >120 μmol/L)
- Known hypersensitivity to Nuwiq's active substance or its excipients (sucrose, sodium chloride, calcium chloride dihydrate, arginine hydrochloride, sodium citrate dihydrate, poloxamer 188)
- Pregnancy, except in participants with a planned caesarean section
- Already had surgery in this study
- Current participation in another interventional clinical trial
- Treatment with any investigational medicinal product (IMP) within 30 days prior to screening visit
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Nuwiq
All patients receiving Nuwiq (recombinant FVIII). Nuwiq will be administered intravenously in accordance with the relevant prescribing information. Treatment will be repeated as necessary every 8-24 hours until adequate wound healing, then - if required - for at least another 7 days to maintain FVIII plasma levels of 30-60 IU/dL. |
Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F). |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall haemostatic efficacy
時間枠:During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
|
Overall haemostatic efficacy of treatment measured as binary "success" or "failure". The overall perioperative haemostatic efficacy of Nuwiq will be adjudicated by an Independent Data Monitoring Committee (IDMC) and determined using a composite assessment algorithm that considers the surgeon's assessment of intraoperative haemostatic efficacy and the investigator's assessment of postoperative haemostatic efficacy to classify the overall haemostatic efficacy as success or failure. |
During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Intraoperative haemostatic efficacy
時間枠:During surgery: From first skin incision to last suture
|
Assessment of intraoperative haemostatic efficacy of Nuwiq using a 4-point ordinal scale: Excellent: Intraoperative blood loss was lower than or equal to the average expected blood loss for the type of procedure performed in a patient with normal haemostasis and of the same sex, age, and stature Good: Intraoperative blood loss was higher than the average expected blood loss but lower or equal to the maximal expected blood loss for the type of procedure in a patient with normal haemostasis. Moderate: Intraoperative blood loss was higher than the maximum expected blood loss for the type of procedure performed in a patient with normal haemostasis, but haemostasis was controlled. None: Haemostasis was uncontrolled, necessitating a change in the clotting factor replacement regimen. |
During surgery: From first skin incision to last suture
|
|
Postoperative haemostatic efficacy
時間枠:During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
|
Assessment of postoperative haemostatic efficacy of Nuwiq using a 4-point ordinal scale: Excellent: No postoperative bleeding or oozing that was not due to complications of surgery. All postoperative bleeding (due to complications of surgery) was controlled with Nuwiq as anticipated for the type of procedure. Good: No postoperative bleeding or oozing that was not due to complications of surgery. Control of postoperative bleeding due to complications of surgery required increased dosing with Nuwiq or additional injections not originally anticipated for the type of procedure. Moderate: Some postoperative bleeding and oozing that was not due to complications of surgery. Control of postoperative bleeding required increased dosing with Nuwiq or additional injections not originally anticipated for the type of procedure. None: Extensive uncontrolled postoperative bleeding and oozing. |
During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
|
|
Allogenic blood products
時間枠:During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
|
Use of allogeneic blood products (red blood cells, platelets, and other blood products) |
During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure
|
|
FVIII plasma levels
時間枠:≤30 minutes before and 15-30 minutes after Nuwiq injection
|
Perioperative plasma levels |
≤30 minutes before and 15-30 minutes after Nuwiq injection
|
|
Perioperative haemostatic efficacy per WFH criteria
時間枠:≤30 minutes before and 15-30 minutes after Nuwiq injection
|
Assessed using 4-point scale recommended by WFH: Excellent: Intra- and post-operative blood loss similar to non-haemophilic patient. No extra doses of FVIII/bypassing agents needed Good: Intra- and/or post-operative blood loss slightly increased over expectation for non-haemophilic patient, but judged to be clinically insignificant. No extra doses of FVIII/bypassing agents needed Fair: Intra- and/or post-operative blood loss increased over expectation for the non-haemophilic patient, and additional treatment needed. Extra dose of FVIII/bypassing agents needed, or increased blood component of anticipated transfusion requirement Poor: Significant intra- and/or post-operative blood loss substantially increased over expectation for non-haemophilic patient, requires intervention not explained by medical issue other than haemophilia. Unexpected hypotension, unexpected transfer to ICU due to bleeding, substantially increased blood component of the anticipated transfusion requirement |
≤30 minutes before and 15-30 minutes after Nuwiq injection
|
|
Adverse events
時間枠:From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
|
Incidence of adverse events recorded during the full study period |
From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
|
|
Thrombotic events
時間枠:From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
|
Incidence of thrombotic events during the study |
From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
|
|
FVIII inhibitor formation
時間枠:From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
|
Incidence of FVIII inhibitor formation |
From start of first Nuwiq injection to 30 ±3 days following the surgical procedure
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Johannes Oldenburg、Experimental Haematology and Transfusion Medicine, University Clinic Bonn
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- GENA-23
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。